The clinical pharmacists of West China Second University Hospital participated in the MDT process of rare diseases in children, and constructed a pharmaceutical service model of MDT of rare diseases in children by formulating drug treatment plans based on evidence-based practice, improving the accessibility of therapeutic drugs, pharmaceutical care, drug treatment management, and participating in the diagnosis and treatment process of children throughout the process.
The article describes a pharmaceutical service model for children with rare diseases. Clinical pharmacists at West China Second University Hospital took part in the multidisciplinary diagnosis and treatment process. They made drug treatment plans based on evidence-based practice and worked on pharmaceutical monitoring and drug treatment management.
The hospital set up a closed pharmaceutical service model that included inpatient and outpatient care and online and offline services. From January 2021 to April 2022, the clinical pharmacists joined 39 pediatric rare disease MDT cases. The study reported that 24 cases involved off-label drug use and that the model improved drug availability and standardized clinical use. This manual is written in Chinese.
From January 2021 to April 2022, they participated in a total of 39 cases of rare diseases MDT in children.
The hospital primarily established a closed-loop pharmaceutical service model of MDT for children with rare diseases.